A Case of Adverse Drug Reactions of Lopinavir and Ritonavir Tablets and Literature Analysis

doi:10.19803/j.1672-8629.2020.07.04

Abstract

Abstract: Objective To analyze the adverse reactions of lopinavir and ritonavir tablets in a COVID-19 patient in order to provide reference for clinical medication. Methods The clinical data of a patient with newly diagnosed COVID -19 in the Third People's Hospital of Hubei province was collected, including medical history, results of physical examination, diagnosis and treatment plans, outcomes of laboratory and imaging examination. The relationships between nausea, vomiting, diarrhea, epistaxis and medication were determined. Results Based on the analysis of the patient's medication and treatment of adverse reactions, and according to the national Provisions for Adverse Drug Reaction Reporting and Monitoring, the correlations of lopinavir and ritonavir with nausea, vomiting, diarrhea and epistaxis were evaluated. It was found that the above symptoms were probably caused by the antiviral drug lopinavir and ritonavir. Conclusion Lopinavir and ritonavir is recommended for the antiviral treatment of COVID -19, but it is worth noting that it is associated with such adverse reactions as nausea, vomiting, diarrhea and interactions with other drugs.

Key words: lopinavir and ritonavir, COVID -19, adverse drug reaction

CLC Number:

R994.1

AN Wei, TIAN Ying, CHEN Min, YANG Ping, ZHANG Mingwei. A Case of Adverse Drug Reactions of Lopinavir and Ritonavir Tablets and Literature Analysis[J]. Chinese Journal of Pharmacovigilance, 2020, 17(7): 399-402.

References

[1] Hui DS, Azhar EI, Madani TA, et al.The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan,China[J]. International Journal of Infectious Disease, 2020,91: 264-266.
[2] Tan WJ, Zhao X, Ma XJ, et al.A novel coronavirus genome ident-ified in a cluster of pneumonia cases-Wuhan China 2019 - 2020[J].China CDC Weekly, 2020, 2(4): 61-62.
[3] Cui J, Li F, Shi Z.Origin and evolution of pathogenic coronaviruses[J].Nature Reviews Microbiology,2019, 17(3): 181-192.
[4] 中华人民共和国国家卫生健康委员会.新型冠状病毒肺炎诊疗方案(试行第六版)[EB/OL].(2020-02-19)[2020-02-19].http://www.nhc.gov.cn/wjw/index.shtml.
[5] 陈利娟,任丽娟. 我中心2011-2014年抗艾滋病毒药物应用分析[J]. 中国药房, 2017, 28(17): 2336-2339.
[6] Bates DE, Herman RJ.Carbamazepine toxicity induced by lopinavir /ritonavir and nelfinavi[J]. The Annals of pharmacotherapy,2006, 40(6): 1190-1195.
[7] Borrs-Blasco J, Bda A, Rosique-Robles D, et al.Hairloss induced by lopinavir /ritonavir[J]. Pharmacotherapy, 2007, 27(8):1215-1218.
[8] Kim HS, Shin HS.Alopecia areata associated with abacavir therapy[J]. Infect Chemother, 2014, 46(2):103-105.
[9] Greffrath WP, Plessis JM, Viljoen M, et al.Hypertriglyceridaemia and the risk of pancreatitis six months post lopinavir/ritonavirinitiation[J]. South Afr J HIV Med, 2018, 19(1): 766.
[10] Bandeira ACPCS, Elias DBD, Cavalcante MG.Antiretroviral changes during the first year of therapy[J]. Rev Assoc Med Bras,2017, 63(7):606-612.
[11] Sunita G, Alecia GK, Boriss YL, et al.Brain Injury Caused by HIV Protease Inhibitors: role of Lipodystrophy and Insulin Resistance[J].Antiviral Res, 2012, 95(1):19-29.
[12] Chu CM, Cheng VCC, Hung IFN, et al.Role of lopinavir /ritonavir in the treatment of SARS:initial virological and clinical findings[J]. Thorax, 2004, 59(3): 252-256.
[13] Chen N, Zhou M, Dong X, et al.Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan,China: a descriptive study[J]. The Lancet, 2020,395(10223): 507-513.
[14] 江华,邓洪飞,王宇,等. 洛匹那韦利托那韦(LPV/r)用于2019新型冠状病毒肺炎的治疗可能性:基于既往冠状病毒肺炎研究的快速系统评价[J]. 中华急诊医学杂志, 2020, 29(2):182-185.
[15] 靳英辉,蔡林,程真顺,等. 新型冠状病毒(2019-nCoV)感染的肺炎诊疗快速建议指南(标准版)[J]. 解放军医学杂志,2020, 45(1): 1-20.